Section 5.1
Inotropic Drugs & Heart Failure Management
Explain the pump problem in heart failure, distinguish long-term protective treatment from symptom relief and inotropes, and recognize mechanism-linked safety concerns.
Learn
Idea 1 / 7
Heart failure does not mean the heart has stopped
The ventricles are the heart’s pumping chambers. Heart failure is a syndrome in which a structural or functional problem causes symptoms such as breathlessness, fatigue or fluid retention. A ventricle may contract weakly, fill poorly, or have both problems. Ejection fraction is the proportion of blood in a filled ventricle that leaves during one beat. Heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction are not interchangeable diagnoses: an apparently preserved fraction does not rule out impaired filling or high filling pressures.
A ventricle containing 100 mL before contraction and ejecting 35 mL has an ejection fraction of 35%. This calculation describes one aspect of pumping; it does not by itself identify the cause or choose a medicine.
Read all essential notes
Heart failure does not mean the heart has stopped
The ventricles are the heart’s pumping chambers. Heart failure is a syndrome in which a structural or functional problem causes symptoms such as breathlessness, fatigue or fluid retention. A ventricle may contract weakly, fill poorly, or have both problems. Ejection fraction is the proportion of blood in a filled ventricle that leaves during one beat. Heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction are not interchangeable diagnoses: an apparently preserved fraction does not rule out impaired filling or high filling pressures.
A ventricle containing 100 mL before contraction and ejecting 35 mL has an ejection fraction of 35%. This calculation describes one aspect of pumping; it does not by itself identify the cause or choose a medicine.
Separate force, filling and resistance
Inotropy means contraction force. Cardiac output is blood pumped per minute: heart rate multiplied by the volume ejected per beat. Preload describes the stretch of ventricular muscle before contraction, related to filling. Afterload is the load the ventricle must overcome to eject blood. These are different levers. More filling can help a healthy heart up to a point, but excessive filling pressure in heart failure can cause congestion: fluid backs up into lungs or tissues. Increasing force, removing excess fluid and reducing resistance therefore solve different parts of the problem.
A loop diuretic can relieve swollen ankles by increasing salt and water excretion without directly increasing contraction force. An inotrope increases force but does not replace assessment of congestion, rhythm or blood pressure.
Long-term HFrEF treatment has a different purpose
For eligible people with HFrEF, foundational treatment combines four medicine groups: an angiotensin receptor–neprilysin inhibitor (ARNI), or an angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) when appropriate; an evidence-based beta blocker; a mineralocorticoid receptor antagonist (MRA); and a sodium-glucose cotransporter-2 (SGLT2) inhibitor. These act on different disease pathways. They are not four names for inotropes. Diuretics address congestion; selected additional medicines may serve other goals. Choice and monitoring depend on stability, blood pressure, kidney function, electrolytes and individual circumstances.
A stable person may receive a beta blocker even though it initially reduces sympathetic stimulation of the heart. Short-term contraction strength and long-term protection are different outcomes; a medicine cannot be judged from one immediate effect alone.
Digoxin has two linked cardiac effects
Digoxin inhibits the sodium–potassium pump in cardiac cells. Normally this pump helps maintain a low sodium concentration inside the cell. Inhibition raises intracellular sodium, reducing the gradient used by the sodium–calcium exchanger to remove calcium. More calcium can then be available for contraction. Separately, digoxin increases vagal influence—the parasympathetic nerve influence that slows conduction through the atrioventricular (AV) node, the electrical relay between atria and ventricles. Thus stronger contraction and a slower ventricular rate can occur together. Digoxin is a selected adjunct, not a replacement for foundational HFrEF treatment.
A slower ventricular response in atrial fibrillation can coexist with stronger contraction, so pulse rate and rhythm are both relevant.
A narrow safety margin makes context important
A narrow therapeutic index means the useful concentration is close to the toxic concentration. Digoxin is largely cleared by the kidneys, so kidney function and interacting medicines matter. Low potassium can increase digoxin binding to its target and raise toxicity risk. Early toxicity may include nausea, vomiting, poor appetite or visual changes; cardiac rhythm changes can be dangerous.
A patient with vomiting and a new irregular pulse after starting digoxin needs prompt clinical review, not an extra dose.
Milrinone links the heart to the vessels
Milrinone inhibits phosphodiesterase-3 (PDE3), an enzyme that breaks down the intracellular messenger cyclic adenosine monophosphate, or cyclic AMP. In cardiac muscle, increased cyclic AMP can strengthen contraction. In vascular smooth muscle, it promotes relaxation. This combination gives the name inodilator: inotrope plus dilator. Lower resistance may help forward flow, but blood pressure may fall and arrhythmias can occur. Milrinone is used intravenously in selected monitored acute situations; it is not a routine long-term oral substitute for protective heart-failure medicines. Kidney impairment can prolong exposure.
If blood flow improves while blood pressure falls during a monitored infusion, both observations can arise from the drug’s mechanism. The clinical team assesses the overall effect rather than labeling every pressure fall as proof of treatment failure or every output increase as proof of safety.
Match each observation to the question it answers
A useful monitoring plan asks several separate questions. Breathlessness, swelling and weight trends help assess congestion. Pulse and an electrocardiogram assess rate and rhythm. Blood pressure and signs of organ perfusion help assess circulation. Kidney function affects drug clearance and treatment tolerance; potassium and magnesium affect electrical stability. A digoxin concentration adds information only when sampling time and the clinical situation are considered. No single normal number rules out toxicity, and symptom improvement does not make adverse effects irrelevant. New marked weakness, fainting or serious rhythm symptoms need prompt clinical assessment.
Less ankle swelling answers a congestion question. It does not tell you whether nausea and a newly slow pulse in someone taking digoxin are harmless. Those findings require their own safety assessment.
Common misconception: “A stronger heartbeat always means a safer, healthier heart.” Inotropes can improve forward flow while increasing arrhythmia, oxygen-demand or hypotension risk.
Explore
Pharmacology · 5.1
Follow the pressure, force and signalling paths
Select a view, follow the numbered arrows, then use the explanation below the plate.
More controls
Filling loads the ventricle · Schematic, not to scale; arrows show a teaching sequence.
Use the mechanism to organise observations; a real treatment decision requires the clinical context and a qualified team.
Go deeper: worked example
A patient receiving digoxin for symptomatic heart failure has poor appetite, nausea, a pulse of 48/min and a recent potassium result below the local reference range. The patient asks whether to take the next dose.
- First separate the treatment goals. The person has heart failure, but the current question is not simply whether contraction is stronger. Poor appetite and nausea are new symptoms, and a pulse of 48 per minute raises a conduction and rhythm concern. Assess the person’s condition rather than interpreting the pulse as an isolated number.
- Connect the findings to digoxin. Its cellular action alters calcium handling, while vagal effects can slow AV conduction. Low potassium increases susceptibility to toxicity. This cluster is concerning, but it is not enough to establish the diagnosis or distinguish every possible rhythm without clinical assessment.
- Look for changes in exposure and vulnerability. Recent kidney impairment, dehydration, a change in another medicine or an incorrect dosing history can matter. A drug level needs an appropriate sampling time; it cannot replace symptoms, an electrocardiogram, kidney function and electrolytes.
- Escalate the immediate safety question promptly to the prescribing or urgent-care team before a further dose decision. Do not calculate a new dose from this classroom example. Recall: which findings concern congestion, and which concern possible toxicity? Here the new gastrointestinal symptoms, bradycardia and low potassium primarily raise the toxicity question.
A plausible toxicity pattern requires assessment of rhythm, electrolytes, renal function and medication timing before the next dose is decided.
Explain it yourself
Why should pulse, potassium and kidney function be interpreted together in a person taking digoxin?
Reveal explanation
They represent linked safety conditions: digoxin can slow conduction and alter excitability, low potassium can increase target binding, and reduced renal clearance can raise exposure.
Create and evaluate
Create a monitoring map from inotrope target to patient observation.
Formative activity: compare your reasoning with the rubric. This response is not automatically graded and does not award mastery. It remains only on this page and is cleared when you leave.
Compare with the rubric and example
- Names the target and links it to force, flow and a specific safety signal.
- Includes rhythm, pressure and relevant kidney or electrolyte context.
- Separates a classroom explanation from a real dose decision requiring a clinician.
Digoxin changes pump-related calcium handling and vagal conduction: contractility may rise and AV conduction may slow. Check pulse and rhythm, potassium and renal function, and investigate nausea or visual changes before any dose decision.
Sources and review status
Educational draft. Medical and French-language expert review pending. External sources require an internet connection; essential explanations are included above.
- Clinical Pharmacology Made Incredibly Easy!, 3rd ed. (2009)
Chapter 5, printed pp. 119–154; PDF pp. 131–166
- DailyMed: digoxin tablets
Mechanism, renal clearance, electrolyte susceptibility and toxicity warnings; accessed 2026-09-21.
- DailyMed: milrinone lactate injection
PDE3 mechanism, short-term IV use, hypotension/arrhythmias and renal impairment; accessed 2026-09-21.
- AHA/ACC/HFSA: heart failure guideline summary
Four foundational HFrEF medication classes; updates the 2009 textbook context. Accessed 2026-09-21.
- American Heart Association: medicines used in heart failure
Patient-oriented explanation of complementary treatment roles; reviewed June2025, accessed 2026-09-21.
Check my understanding
Mastery Question Gate
Answer all questions correctly to unlock the next lesson. Retakes vary the selection when enough questions are available; some questions may repeat.
1. Which electrolyte imbalance significantly increases the risk of digoxin toxicity?